Skip to main content
Fig. 1 | Clinical Epigenetics

Fig. 1

From: Cell-free DNA 5-hydroxymethylcytosine profiles of long non-coding RNA genes enable early detection and progression monitoring of human cancers

Fig. 1

Workflow diagram of the study design. A three-phase discovery–modeling–validation study was conducted, including a total of 3011 samples (1632 cancers and 1379 non-cancerous samples). During the discovery phase, plasma-derived abnormal 5hmC-modified lncRNA genes were identified in Li’s cohort comprising HCC (n = 25), CC (n = 78), GC (n = 62) and healthy (n = 96) samples. The 5hmC-modified lncRNA-based predictive models for cancer diagnosis and classification were then constructed using Bagged CART with tenfold cross-validation and elastic net regularization in the training cohort, followed by validation in different independent cohorts from multiple centers. lncRNA, long non-coding RNA; CART, classification and regression tree; CC, colon cancer; CHB, chronic hepatitis B virus infection; EC, esophageal cancer; GC, gastric cancer; HCC, hepatocellular carcinoma; NSCLC, non-small-cell lung cancer; 5hmC, 5-hydroxymethylcytosine; 5hLD-score, 5hmC-LncRNA diagnostic score; 5hLC-score, 5hmC-lncRNA classification score

Back to article page

Clinical Epigenetics

ISSN: 1868-7083

Contact us